{"analyses":[{"ciLowerLimit":"-0.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.7","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.10","paramType":"Mean Difference (Final Values)","paramValue":"0.7","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":".5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"852"},{"groupId":"OG001","value":"837"}],"units":"Participants"}],"description":"To compare the incidence of renal dysfunction of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The percentage of patients with renal dysfunction, defined as grade 3 or grade 4 increased creatinine (Common Terminology Criteria for Adverse Events version 3.0), will be reported here.","groups":[{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Zoledronic Acid Every 4 Weeks)"},{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Zoledronic Acid Every 12 Weeks)"}],"paramType":"NUMBER","populationDescription":"1689 patients completed treatment and were analyzed.","reportingStatus":"POSTED","timeFrame":"from baseline up to 2 years","title":"Incidence of Renal Dysfunction","type":"SECONDARY","unitOfMeasure":"percentage of participants"}